The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Atezolizumab plus personalized neoantigen vaccination (PGV001) in patients with urothelial cancer.
 
Jonathan Forrest Anker
Patents, Royalties, Other Intellectual Property - Co-inventor on patent "IMMUNOSTIMULATORY BACTERIA FOR THE TREATMENT OF CANCER", Publication number 20190046588 (Inst)
 
Mansi Saxena
No Relationships to Disclose
 
Julia Kodysh
No Relationships to Disclose
 
Timothy O'Donnell
No Relationships to Disclose
 
Marcia Meseck
No Relationships to Disclose
 
Olivia Hapanowicz
No Relationships to Disclose
 
Scot Anthony Niglio
Employment - STEMCELL Technologies (I)
Other Relationship - STEMCELL Technologies (I)
 
Hardik R. Shah
No Relationships to Disclose
 
Yayoi Kinoshita
No Relationships to Disclose
 
Rachel Brody
No Relationships to Disclose
 
Alex Rubinsteyn
No Relationships to Disclose
 
Robert P. Sebra
Stock and Other Ownership Interests - GeneDx/BioReference
Consulting or Advisory Role - GeneDx/BioReference
 
Nina Bhardwaj
Leadership - American Association for Cancer Research
Stock and Other Ownership Interests - Apricity Health; Genotwin; PrimeVax
Honoraria - Pfizer; U.S. Food and Drug Administration
Consulting or Advisory Role - American Association for Cancer Research; Apricity Health; BioNTech SE; Boehringer Ingelheim; BreakBio Corp.; Carisma Therapeutics; CureVac; Genotwin; Gilead Sciences; Novartis; Parker Institute for Cancer Immunotherapy; PrimeVax; Roche/Genentech; rome; Rubius Therapeutics; Tempest Therapeutics
Research Funding - Celldex (Inst); Genentech (Inst); Novocure (Inst); Oncovir (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Parker Institute for Cancer Immunotherapy
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Abbvie; Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792